@article{bbf86d0c5a7c4d828e46c4e58694a179,
title = "Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities",
abstract = "Introduction: Blood-based biomarkers of amyloid pathology and neurodegeneration are entering clinical use. It is critical to understand what factors affect the levels of these markers. Methods: Plasma markers (Aβ42, Aβ40, NfL, T-tau, Aβ42/40 ratio) were measured on the Quanterix Simoa HD-1 analyzer for 996 Mayo Clinic Study of Aging (MCSA) participants, aged 51 to 95 years. All other data were collected during in-person MCSA visits or abstracted from the medical record. Results: Among cognitively unimpaired (CU) participants, all plasma markers correlated with age. Linear regression models revealed multiple relationships. For example, higher Charlson Comorbidity Index and chronic kidney disease were associated with higher levels of all biomarkers. Some relationships differed between mild cognitive impairment and dementia participants. Discussion: Multiple variables affect plasma biomarkers of amyloid pathology and neurodegeneration among CU in the general population. Incorporating this information is critical for accurate interpretation of the biomarker levels and for the development of reference ranges.",
keywords = "amyloid, cognition, comorbid conditions, demographics, neurofilament light chain, total tau",
author = "Syrjanen, {Jeremy A.} and Campbell, {Michelle R.} and Alicia Algeciras-Schimnich and Prashanthi Vemuri and Jonathan Graff-Radford and Machulda, {Mary M.} and Guojun Bu and Knopman, {David S.} and Jack, {Clifford R.} and Petersen, {Ronald C.} and Mielke, {Michelle M.}",
note = "Funding Information: Funding for this study was provided by grants from the National Institutes of Health (U01 AG006786, R37 AG011378, R01 NS097495, and P30 AG062677) and the GHR Foundation. This study was made possible using the resources of the Rochester Epidemiology Project, which is supported by the National Institute on Aging of the National Institutes of Health under Award Number R01 AG034676. Funding Information: Dr. Mielke served as a consultant to Brain Protection Company and Biogen and receives research support from the National Institutes of Health and the Department of Defense. She is a Senior Associate Editor for . Dr. Knopman serves on a Data Safety Monitoring Board for Biogen (fee paid to institution), the DIAN‐TU study (receives personal consulting fees), Agenbio (unpaid), and an endovascular carotid reconstruction study (unpaid). He is an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the Alzheimer's Disease Cooperative Study, and receives research support from the National Institutes of Health and philanthropic funds. Dr. Bu has received consulting and/or speaking fees from AbbView, E‐Scape, SciNeuro, Merck, and Alnylam. He receives research support from the National Institutes of Health and the Cure Alzheimer's Fund, has a patent pending for application of Wnt modulators, and serves as a member of the Scientific Review Committee for the Bright Focus Foundation and Research Leadership Group for Cure Alzheimer's Fund. Dr. Vemuri received speaking fees from Miller Medical Communications, LLC, and receives research support from the National Institutes of Health. Dr Graff‐Radford receives NIH funding and serves as Assistant Editor for . He has received payment for speaking at the American Academy of Neurology Annual meeting. Dr. Jack serves on an independent data monitoring board for Roche, but he receives no personal compensation from any commercial entity. He receives research support from the National Institutes of Health, the GHR Foundation and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. Dr. Petersen is a consultant for Roche, Inc., Merck, Inc., Biogen, Inc., and Eisai, Inc. He has received payment for serving on a Data Safety Monitoring Board for Genentech, receives royalties from Oxford University Press and UpToDate, and receives research support from the National Institutes of Health. Dr. Machulda receives research support from the National Institutes of Health. Ms. Campbell has served in unpaid leadership roles for The American Society for Clinical Laboratory Science, American Society for Clinical Pathology, and the Clinical Laboratory Standards Institute. Mr. Syrjanen and Dr. Algeciras‐Schimnich have no conflicts to report. Alzheimer's and Dementia: The Journal of the Alzheimer's Association Neurology Publisher Copyright: {\textcopyright} 2021 the Alzheimer's Association.",
year = "2022",
month = jun,
doi = "10.1002/alz.12466",
language = "English (US)",
volume = "18",
pages = "1128--1140",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "6",
}